Clinical Trials in Croatia

• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended
  2022-501176-26-00 Phase III Acute Ischemic Stroke and High-Risk Transient Ischemic Attac… Janssen - Cilag International
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended
  2022-501939-16-00 Phase III Heart failure (HF) with mildly reduced ejection fraction (HF… Novo Nordisk A/S
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended
  2023-504741-32-00 Phase II Moderately to Severely Active Crohn's Disease Janssen - Cilag International
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended
  2023-504743-13-00 Phase II Moderately to Severely Active Ulcerative Colitis Janssen - Cilag International
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended
  2023-505579-53-00 Phase III Diffuse large B-cell lymphoma (DLBCL) Incyte Corp.
• A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow Ended
  2023-506927-27-00 Phase III Children with short stature either born small for gestationa… Novo Nordisk A/S
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended
  2024-514630-21-00 Phase II HER2 positive (HER2+), Hormone Receptor positive (HR+) Early… Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended
  2023-505974-14-00 Phase III Multiple Sclerosis (MS) F. Hoffmann-La Roche AG
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509345-12-00 Phase III Multiple Sclerosis Novartis Pharma AG
• GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended
  2023-504737-41-00 Phase III Moderately to Severely Active Crohn's Disease Janssen - Cilag International
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended
  2023-507795-51-00 Phase III atherosclerotic heart and blood vessel disease (the narrowin… NewAmsterdam Pharma B.V.
• A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular A… Ended
  2023-506761-65-00 Phase II/III Spinal Muscular Atrophy (SMA) F. Hoffmann-La Roche AG
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended
  2023-506516-40-00 Phase III Relapsing-Remitting Multiple Sclerosis F. Hoffmann-La Roche AG
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509372-41-00 Phase III Multiple Sclerosis Novartis Pharma AG
• A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis Ended
  2022-502619-13-00 Phase II Relapsing Multiple Sclerosis F. Hoffmann-La Roche AG
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III Atherosclerotic cardiovascular disease (ASCVD) Novartis Pharma AG
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended
  2023-507494-18-00 Phase III Non-small cell lung cancer with ROS proto-oncogene 1, recept… F. Hoffmann-La Roche AG
• Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3) Ended
  2023-503772-24-00 Phase II/III IgA Nephropathy Vera Therapeutics Inc.
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended
  2023-504734-21-00 Phase III Psoriatic arthritis (PsA) Janssen - Cilag International
• DALY 2-EU Ended
  2023-506270-13-00 Phase II Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL… Miltenyi Biomedicine GmbH
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended
  2023-507697-40-00 Phase III Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Loxo Oncology Inc.
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended
  2022-502122-41-00 Phase III Clear cell renal cancer Merck Sharp & Dohme LLC
• A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended
  2023-503229-21-00 Phase III Unresectable hepatocellular carcinoma (HCC) F. Hoffmann-La Roche AG
• Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended
  2023-505615-21-00 Phase III Muscle Invasive Bladder Cancer Merck Sharp & Dohme LLC

Showing 169–192 of 276 trials